Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novasep Appoints President and CEO

Published: Thursday, June 27, 2013
Last Updated: Thursday, June 27, 2013
Bookmark and Share
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.

He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.

Over the past months Novasep’s growth has gained momentum with significant new investments in Mourenx (France), to build the world’s largest chromatography plant dedicated to the pharmaceutical industry, in Le Mans (France) to expand manufacturing capabilities of cutting-edge anti-cancer therapies and in Shanghai (China) to better serve its clients in Asia. Roger-Marc Nicoud, Founder and Non-Executive Chairman of the Board of Novasep, said: “We are delighted to welcome Michel Spagnol to Novasep as CEO.His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience and longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the Company. He has all the qualities required to consolidate and accelerate Novasep’s development. On behalf of the Board, I would like to thank Patrick Glaser for his contributions as the CEO of the Company and accomplishments as Head of Novasep Synthesis. Over the past years, Novasep has grown significantly under his leadership, and he has developed a solid foundation for Michel Spagnol to build upon.”

Michel Spagnol, new CEO, declared: “Novasep is a world leader in purification technologies with differentiated capabilities in hazardous chemistry and high potency chemistry and is well positioned to serve the pharmaceutical, fine chemical, bio-pharma and industrial biotech industries. I am very pleased to be given the opportunity to lead the Company. I am looking forward to working closely with all my new colleagues. Novasep is on the right track for continued growth and expansion with promising projects which will enable us to continue delivering value-added solutions for our global customers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep and instrAction Enter into a Worldwide Strategic Alliance for Non-Chiral Chromatography
Combination of instrAction and Novasep know-how sets a new standard for small molecule purification processes for the life science industries.
Tuesday, July 20, 2010
Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen
Acquisition of upstream processing capabilities and services enables Novasep to offer full-range of biomanufacturing solutions.
Wednesday, July 08, 2009
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos